HES5 silencing is an early and recurrent change in prostate tumourigenesis

Endocrine-Related Cancer

Volumn 22, Issue 2, 2015, Pages 131-144

  Massie, Charles E ^a   Spiteri, Inmaculada ^a   Ross Adams, Helen ^a   Luxton, Hayley ^a   Kay, Jonathan ^a   Whitaker, Hayley C ^a   Dunning, Mark J ^a   Lamb, Alastair D ^a,e   Ramos Montoya, Antonio ^a   Brewer, Daniel S ^c   Cooper, Colin S ^b,c   Eeles, Rosalind ^b,d   Warren, Anne Y ^e   Tavaré, Simon ^a   Neal, David E ^a,e   Lynch, Andy G ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

AR; Epigenetics; ERG; HES5; HES6; Methylation; NOTCH; Prostate cancer

Indexed keywords

TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR HES 1; TRANSCRIPTION FACTOR HES 5; TRANSCRIPTION FACTOR HES 6; UNCLASSIFIED DRUG; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; ERG PROTEIN, HUMAN; HES5 PROTEIN, HUMAN; REPRESSOR PROTEIN; TRANSACTIVATOR PROTEIN;

ARTICLE; CANCER RECURRENCE; CARCINOGENESIS; COHORT ANALYSIS; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; ERG GENE; FUSION GENE; GENE; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENE REARRANGEMENT; GENE SILENCING; GENETIC TRANSCRIPTION; INVESTIGATIVE PROCEDURES; PROMOTER REGION; PROSTATE CANCER; PROSTATE CANCEROGENESIS; UNITED KINGDOM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HUMAN; MALE; METABOLISM; PROSTATE TUMOR; TUMOR CELL LINE;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARCINOGENESIS; CELL LINE, TUMOR; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; REPRESSOR PROTEINS; TRANS-ACTIVATORS;

EID: 84929310043     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-14-0454     Document Type: Article

References (78)

1. Alcolea MP, Greulich P, Wabik A, Frede J, Simons BD & Jones PH 2014 Differentiation imbalance in single oesophageal progenitor cells causes clonal immortalization and field change. Nature Cell Biology 16 615-622. (doi:10.1038/ncb2963)
2. Annala M, Kivinummi K, Leinonen K, Tuominen J, Zhang W, Visakorpi T & Nykter M 2014 DOT1L-HES6 fusion drives androgen independent growth in prostate cancer. EMBO Molecular Medicine 6 1121-1123. (doi:10.15252/emmm.201404210)
3. Aryee MJ, Jaffe AE, Corrada-Bravo H, Ladd-Acosta C, Feinberg AP, Hansen KD & Irizarry RA 2014 Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. Bioinformatics 30 1363-1369. (doi:10.1093/bioinformatics/btu049)
4. Austin DW, Allen MS, McCollum JM, Dar RD, Wilgus JR, Sayler GS, Samatova NF, Cox CD & Simpson ML 2006 Gene network shaping of inherent noise spectra. Nature 439 608-611. (doi:10.1038/nature04194)
5. Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, Drier Y, Park K, Kitabayashi N, MacDonald TY, Ghandi M et al. 2013 Punctuated evolution of prostate cancer genomes. Cell 153 666-677. (doi:10.1016/j.cell.2013.03.021)
6. Bae S, Bessho Y, Hojo M & Kageyama R 2000 The bHLH gene Hes6, an inhibitor of Hes1, promotes neuronal differentiation. Development 127 2933-2943.
7. Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, White TA, Stojanov P, Van Allen E, Stransky N et al. 2012 Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nature Genetics 44 685-689. (doi:10.1038/ng.2279)
8. Barry M, Perner S, Demichelis F & Rubin MA 2007 TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. Urology 70 630-633. (doi:10.1016/j.urology.2007.08.032)
9. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C et al. 2011 The genomic complexity of primary human prostate cancer. Nature 470 214-220. (doi:10.1038/nature09744)
10. Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch AM, Wu J et al. 2012 Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491 399-405. (doi:10.1038/nature11547)
11. Bolton EC, So AY, Chaivorapol C, Haqq CM, Li H & Yamamoto KR 2007 Cell- and gene-specific regulation of primary target genes by the androgen receptor. Genes and Development 21 2005-2017. (doi:10.1101/gad.1564207)
12. Bostwick DG, Shan A, Qian J, Darson M, Maihle NJ, Jenkins RB & Cheng L 1998 Independent origin of multiple foci of prostatic intraepithelial neoplasia: comparison with matched foci of prostate carcinoma. Cancer 83 1995-2002. (doi:10.1002/(SICI)1097-0142(19981101)83:9〈1995::AID-CNCR16〉3.0.CO;2-2)
13. Caini S, Gandini S, Dudas M, Bremer V, Severi E & Gherasim A 2014 Sexually transmitted infections and prostate cancer risk: a systematic review and meta-analysis. Cancer Epidemiology 38 329-338. (doi:10.1016/j.canep.2014.06.002)
14. Cairns JM, Dunning MJ, Ritchie ME, Russell R & Lynch AG 2008 BASH: a tool for managing BeadArray spatial artefacts. Bioinformatics 24 2921-2922. (doi:10.1093/bioinformatics/btn557)
15. Cancer Genome Atlas Network 2012 Comprehensive molecular characterization of human colon and rectal cancer. Nature 487 330-337. (doi:10.1038/nature11252)
16. Cancer Genome Atlas Research Network 2011 Integrated genomic analyses of ovarian carcinoma. Nature 474 609-615. (doi:10.1038/nature10166)
17. Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, Alimonti A, Nardella C, Varmeh S, Scardino PT et al. 2009 Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nature Genetics 41 619-624. (doi:10.1038/ng.370)
18. Chen Y, Chi P, Rockowitz S, Iaquinta PJ, Shamu T, Shukla S, Gao D, Sirota I, Carver BS, Wongvipat J et al. 2013 ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nature Medicine 19 1023-1029. (doi:10.1038/nm.3216)
19. Davis S & Meltzer PS 2007 GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor. Bioinformatics 23 1846-1847. (doi:10.1093/bioinformatics/btm254)
20. Dunning MJ, Smith ML, Ritchie ME & Tavare S 2007 beadarray: R classes and methods for Illumina bead-based data. Bioinformatics 23 2183-2184. (doi:10.1093/bioinformatics/btm311)
21. Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Ghoussaini M, Luccarini C, Dennis J, Jugurnauth-Little S et al. 2013 Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nature Genetics 45 385-391. 391e381-382. (doi:10.1038/ng.2560)
22. Elkahwaji JE, Hauke RJ & Brawner CM 2009 Chronic bacterial inflammation induces prostatic intraepithelial neoplasia in mouse prostate. British Journal of Cancer 101 1740-1748. (doi:10.1038/sj.bjc.6605370)
23. Fior R & Henrique D 2005 A novel hes5/hes6 circuitry of negative regulation controls Notch activity during neurogenesis. Developmental Biology 281 318-333. (doi:10.1016/j.ydbio.2005.03.017)
24. Freedland SJ 2005 Obesity and prostate cancer: a growing problem. Clinical Cancer Research 11 6763-6766. (doi:10.1158/1078-0432.CCR-05-1305)
25. Garcia AJ, Ruscetti M, Arenzana TL, Tran LM, Bianci-Frias D, Sybert E, Priceman SJ, Wu L, Nelson PS, Smale ST et al. 2014 Pten null prostate epithelium promotes localized myeloid-derived suppressor cell expansion and immune suppression during tumor initiation and progression. Molecular and Cellular Biology 34 2017-2028. (doi:10.1128/MCB.00090-14)
26. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC et al. 2012 The mutational landscape of lethal castration-resistant prostate cancer. Nature 487 239-243. (doi:10.1038/nature11125)
27. Hanson JA, Gillespie JW, Grover A, Tangrea MA, Chuaqui RF, Emmert-Buck MR, Tangrea JA, Libutti SK, Linehan WM & Woodson KG 2006 Gene promoter methylation in prostate tumor-associated stromal cells. Journal of the National Cancer Institute 98 255-261. (doi:10.1093/jnci/djj051)
28. Hatakeyama J, Bessho Y, Katoh K, Ookawara S, Fujioka M, Guillemot F & Kageyama R 2004 Hes genes regulate size, shape and histogenesis of the nervous system by control of the timing of neural stem cell differentiation. Development 131 5539-5550. (doi:10.1242/dev.01436)
29. Hatakeyama J, Sakamoto S & Kageyama R 2006 Hes1 and Hes5 regulate the development of the cranial and spinal nerve systems. Developmental Neuroscience 28 92-101. (doi:10.1159/000090756)
30. Heaphy CM, Yoon GS, Peskoe SB, Joshu CE, Lee TK, Giovannucci E, Mucci LA, Kenfield SA, Stampfer MJ, Hicks JL et al. 2013 Prostate cancer cell telomere length variability and stromal cell telomere length as prognostic markers for metastasis and death. Cancer Discovery 3 1130-1141. (doi:10.1158/2159-8290.CD-13-0135)
31. Hitoshi S, Ishino Y, Kumar A, Jasmine S, Tanaka KF, Kondo T, Kato S, Hosoya T, Hotta Y & Ikenaka K 2011 Mammalian Gcm genes induce Hes5 expression by active DNA demethylation and induce neural stem cells. Nature Neuroscience 14 957-964. (doi:10.1038/nn.2875)
32. Jacobsen KX, Vanderluit JL, Slack RS & Albert PR 2008 HES1 regulates 5-HT1A receptor gene transcription at a functional polymorphism: essential role in developmental expression. Molecular and Cellular Neurosciences 38 349-358. (doi:10.1016/j.mcn.2008.03.007)
33. Jia L, Berman BP, Jariwala U, Yan X, Cogan JP, Walters A, Chen T, Buchanan G, Frenkel B & Coetzee GA 2008 Genomic androgen receptor-occupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacity. PLoS ONE 3 e3645. (doi:10.1371/journal.pone.0003645)
34. Kalaany NY & Sabatini DM 2009 Tumours with PI3K activation are resistant to dietary restriction. Nature 458 725-731. (doi:10.1038/nature07782)
35. Kanwal R, Pandey M, Bhaskaran N, Maclennan GT, Fu P, Ponsky LE & Gupta S 2014 Protection against oxidative DNA damage and stress in human prostate by glutathione S-transferase P1. Molecular Carcinogenesis 53 8-18. (doi:10.1002/mc.21939)
36. Kote-Jarai Z, Olama AA, Giles GG, Severi G, Schleutker J, Weischer M, Campa D, Riboli E, Key T, Gronberg H et al. 2011 Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nature Genetics 43 785-791. (doi:10.1038/ng.882)
37. Krueger F & Andrews SR 2011 Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications. Bioinformatics 27 1571-1572. (doi:10.1093/bioinformatics/btr167)
38. Kwon OJ, Zhang L, Ittmann MM & Xin L 2014 Prostatic inflammation enhances basal-to-luminal differentiation and accelerates initiation of prostate cancer with a basal cell origin. PNAS 111 E592-E600. (doi:10.1073/pnas.1318157111)
39. Lee WH, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, Hsieh WS, Isaacs WB & Nelson WG 1994 Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. PNAS 91 11733-11737. (doi:10.1073/pnas.91.24.11733)
40. Lin B, Wang J, Hong X, Yan X, Hwang D, Cho JH, Yi D, Utleg AG, Fang X, Schones DE et al. 2009 Integrated expression profiling and ChIP-seq analyses of the growth inhibition response program of the androgen receptor. PLoS ONE 4 e6589. (doi:10.1371/journal.pone.0006589)
41. Lindberg J, Klevebring D, Liu W, Neiman M, Xu J, Wiklund P, Wiklund F, Mills IG, Egevad L & Gronberg H 2013 Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins. European Urology 63 347-353. (doi:10.1016/j.eururo.2012.03.050)
42. Longabaugh WJ 2012 BioTapestry: a tool to visualize the dynamic properties of gene regulatory networks. Methods in Molecular Biology 786 359-394. (doi:10.1007/978-1-61779-292-2-21)
43. Marabita F, Almgren M, Lindholm ME, Ruhrmann S, Fagerstrom-Billai F, Jagodic M, Sundberg CJ, Ekstrom TJ, Teschendorff AE, Tegner J et al. 2013 An evaluation of analysis pipelines for DNA methylation profiling using the Illumina Human Methylation 450 BeadChip platform. Epigenetics 8 333-346. (doi:10.4161/epi.24008)
44. Massie CE, Adryan B, Barbosa-Morais NL, Lynch AG, Tran MG, Neal DE & Mills IG 2007 New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Reproduction 8 871-878. (doi:10.1038/sj.embor.7401046)
45. Massie CE, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L, Warren A, Scott H, Madhu B, Sharma N et al. 2011 The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO Journal 30 2719-2733. (doi:10.1038/emboj.2011.158)
46. Mehrotra J, Varde S, Wang H, Chiu H, Vargo J, Gray K, Nagle RB, Neri JR & Mazumder A 2008 Quantitative, spatial resolution of the epigenetic field effect in prostate cancer. Prostate 68 152-160. (doi:10.1002/pros.20675)
47. Mertz KD, Horcic M, Hailemariam S, D'Antonio A, Dirnhofer S, Hartmann A, Agaimy A, Eppenberger-Castori S, Obermann E, Cathomas G et al. 2013 Heterogeneity of ERG expression in core needle biopsies of patients with early prostate cancer. Human Pathology 44 2727-2735. (doi:10.1016/j.humpath.2013.07.019)
48. Minner S, Gartner M, Freudenthaler F, Bauer M, Kluth M, Salomon G, Heinzer H, Graefen M, Bokemeyer C, Simon R et al. 2013 Marked heterogeneity of ERG expression in large primary prostate cancers. Modern Pathology 26 106-116. (doi:10.1038/modpathol.2012.130)
49. Mounir Z, Lin F, Lin VG, Korn JM, Yu Y, Valdez R, Aina OH, Buchwalter G, Jaffe AB, Korpal M et al. 2014 TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation. Oncogene [in press]. (doi:10.1038/onc.2014.308)
50. Nevozhay D, Adams RM, Murphy KF, Josic K & Balazsi G 2009 Negative autoregulation linearizes the dose-response and suppresses the heterogeneity of gene expression. PNAS 106 5123-5128. (doi:10.1073/pnas.0809901106)
51. Nik-Zainal S, Van Loo P, Wedge DC, Alexandrov LB, Greenman CD, Lau KW, Raine K, Jones D, Marshall J, Ramakrishna M et al. 2012 The life history of 21 breast cancers. Cell 149 994-1007. (doi:10.1016/j.cell.2012.04.023)
52. Paziewska A, Dabrowska M, Goryca K, Antoniewicz A, Dobruch J, Mikula M, Jarosz D, Zapala L, Borowka A & Ostrowski J 2014 DNA methylation status is more reliable than gene expression at detecting cancer in prostate biopsy. British Journal of Cancer 111 781-789. (doi:10.1038/bjc.2014.337)
53. Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Setlur S, Tchinda J, Tomlins SA, Hofer MD, Pienta KG et al. 2006 TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Research 66 8337-8341. (doi:10.1158/0008-5472.CAN-06-1482)
54. Pollock RF & Adryan B 2008 BioSAVE: display of scored annotation within a sequence context. BMC Bioinformatics 9 157. (doi:10.1186/1471-2105-9-157)
55. Ramos-Montoya A, Lamb AD, Russell R, Carroll T, Jurmeister S, Galeano-Dalmau N, Massie CE, Boren J, Bon H, Theodorou V et al. 2014 HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network. EMBO Molecular Medicine 6 651-661. (doi:10.1002/emmm.201303581)
56. R-Core-Team 2014 R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing.
57. Rosenfeld N, Elowitz MB & Alon U 2002 Negative autoregulation speeds the response times of transcription networks. Journal of Molecular Biology 323 785-793. (doi:10.1016/S0022-2836(02)00994-4)
58. Salama-Cohen P, Arevalo MA, Meier J, Grantyn R & Rodriguez-Tebar A 2005 NGF controls dendrite development in hippocampal neurons by binding to p75NTR and modulating the cellular targets of Notch. Molecular Biology of the Cell 16 339-347. (doi:10.1091/mbc.E04-05-0438)
59. Sancho R, Blake SM, Tendeng C, Clurman BE, Lewis J & Behrens A 2013 Fbw7 repression by hes5 creates a feedback loop that modulates Notch-mediated intestinal and neural stem cell fate decisions. PLoS Biology 11 e1001586. (doi:10.1371/journal.pbio.1001586)
60. Sharma NL, Massie CE, Ramos-Montoya A, Zecchini V, Scott HE, Lamb AD, MacArthur S, Stark R, Warren AY, Mills IG et al. 2013 The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. Cancer Cell 23 35-47. (doi:10.1016/j.ccr.2012.11.010)
61. Shen-Orr SS, Milo R, Mangan S & Alon U 2002 Network motifs in the transcriptional regulation network of Escherichia coli. Nature Genetics 31 64-68. (doi:10.1038/ng881)
62. Sommerfeld HJ, Meeker AK, Piatyszek MA, Bova GS, Shay JW & Coffey DS 1996 Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Research 56 218-222.
63. Statham AL, Robinson MD, Song JZ, Coolen MW, Stirzaker C & Clark SJ 2012 Bisulfite sequencing of chromatin immunoprecipitated DNA (BisChIP-seq) directly informs methylation status of histone-modified DNA. Genome Research 22 1120-1127. (doi:10.1101/gr.132076.111)
64. Takayama K, Kaneshiro K, Tsutsumi S, Horie-Inoue K, Ikeda K, Urano T, Ijichi N, Ouchi Y, Shirahige K, Aburatani H et al. 2007 Identification of novel androgen response genes in prostate cancer cells by coupling chromatin immunoprecipitation and genomic microarray analysis. Oncogene 26 4453-4463. (doi:10.1038/sj.onc.1210229)
65. Tarpey PS, Behjati S, Cooke SL, Van Loo P, Wedge DC, Pillay N, Marshall J, O'Meara S, Davies H, Nik-Zainal S et al. 2013 Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma. Nature Genetics 45 923-926. (doi:10.1038/ng.2668)
66. Tateya T, Imayoshi I, Tateya I, Ito J & Kageyama R 2011 Cooperative functions of Hes/Hey genes in auditory hair cell and supporting cell development. Developmental Biology 352 329-340. (doi:10.1016/j.ydbio.2011.01.038)
67. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R et al. 2005 Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310 644-648. (doi:10.1126/science.1117679)
68. Turatsinze JV, Thomas-Chollier M, Defrance M & van Helden J 2008 Using RSAT to scan genome sequences for transcription factor binding sites and cis-regulatory modules. Nature Protocols 3 1578-1588. (doi:10.1038/nprot.2008.97)
69. Varley KE, Gertz J, Bowling KM, Parker SL, Reddy TE, Pauli-Behn F, Cross MK, Williams BA, Stamatoyannopoulos JA, Crawford GE et al. 2013 Dynamic DNA methylation across diverse human cell lines and tissues. Genome Research 23 555-567. (doi:10.1101/gr.147942.112)
70. Wang Q, Li W, Liu XS, Carroll JS, Jänne OA, Keeton EK, Chinnaiyan AM, Pienta KJ & Brown M 2007 A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Molecular Cell 27 380-392. (doi:10.1016/j.molcel.2007.05.041)
71. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M et al. 2009 Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138 245-256. (doi:10.1016/j.cell.2009.04.056)
72. Warren AY, Whitaker HC, Haynes B, Sangan T, McDuffus LA, Kay JD & Neal DE 2013 Method for sampling tissue for research which preserves pathological data in radical prostatectomy. Prostate 73 194-202. (doi:10.1002/pros.22556)
73. Weaver JM, Ross-Innes CS, Shannon N, Lynch AG, Forshew T, Barbera M, Murtaza M, Ong CA, Lao-Sirieix P, Dunning MJ et al. 2014 Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. Nature Genetics 46 837-843. (doi:10.1038/ng.3013)
74. Wei GH, Badis G, Berger MF, Kivioja T, Palin K, Enge M, Bonke M, Jolma A, Varjosalo M, Gehrke AR et al. 2010 Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo. EMBO Journal 29 2147-2160. (doi:10.1038/emboj.2010.106)
75. Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, Shmulevich I, Sander C & Stuart JM 2013 The Cancer Genome Atlas Pan-Cancer analysis project. Nature Genetics 45 1113-1120. (doi:10.1038/ng.2764)
76. Weischenfeldt J, Simon R, Feuerbach L, Schlangen K, Weichenhan D, Minner S, Wuttig D, Warnatz HJ, Stehr H, Rausch T et al. 2013 Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell 23 159-170. (doi:10.1016/j.ccr.2013.01.002)
77. Yan J, Enge M, Whitington T, Dave K, Liu J, Sur I, Schmierer B, Jolma A, Kivioja T, Taipale M et al. 2013 Transcription factor binding in human cells occurs in dense clusters formed around cohesin anchor sites. Cell 154 801-813. (doi:10.1016/j.cell.2013.07.034)
78. Yu J, Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, Wang X, Wu L, Li J, Hu M et al. 2010 An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 17 443-454. (doi:10.1016/j.ccr.2010.03.018)